Inari Medical, Inc. ((NARI)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The Protrieve PROTECTOR Study, officially titled ‘PROTECTOR: Evaluating the Safety and Effectiveness of the Protrieve Sheath in Preventing Clinically Significant Intraprocedural Pulmonary Embolism by Providing Embolic Protection in the IVC During Thrombectomy Procedures to Treat DVT,’ aims to assess the safety and efficacy of the Protrieve Sheath. This study is significant as it addresses the prevention of pulmonary embolism during thrombectomy procedures, a critical concern in treating deep vein thrombosis (DVT).
The intervention being tested is the Protrieve Sheath, an experimental device designed for embolic protection in the inferior vena cava (IVC) during mechanical thrombectomy procedures. Its purpose is to prevent clinically significant intraprocedural pulmonary embolism, particularly in patients at high risk of embolization.
This is an interventional study with a single-group assignment, focusing on prevention. There is no masking involved, meaning all participants and researchers are aware of the treatment being administered. The study does not involve allocation or observational models, emphasizing its preventive primary purpose.
The study began on March 5, 2025, with its primary completion and estimated completion dates yet to be determined. The last update was submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The update on this study could influence Inari Medical’s stock performance and investor sentiment positively, as successful outcomes may enhance the company’s market position in embolic protection devices. Investors should also consider the competitive landscape, as advancements in similar technologies by other companies could impact market dynamics.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.